These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7165489)

  • 21. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioimmunotherapy of carcinoma of colon with [131I]-labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen.
    Lu QJ; Bian GX; Chen YY; Zhang M; Guo SM; Wen LQ
    Acta Pharmacol Sin; 2005 Oct; 26(10):1259-64. PubMed ID: 16174444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Serological studies using clostridial spores for tumor diagnosis. I. Transplantable tumors in rats and hamsters].
    Kretschmer H; Grässer A
    Arch Geschwulstforsch; 1973; 41(1):12-7. PubMed ID: 4700691
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
    Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
    Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing localization of labeled antibodies in tumors.
    Bale WF; Contreras MA; Grady ED
    Cancer Res; 1980 Aug; 40(8 Pt 2):2965-72. PubMed ID: 7397692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen.
    Goldenberg DM; Gaffar SA; Bennett SJ; Beach JL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4354-60. PubMed ID: 7306964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:nontumor ratio in experimental radioimmunolocalization.
    Ullén A; Sandström P; Ahlström KR; Sundström B; Nilsson B; Arlestig L; Stigbrand T
    Cancer Res; 1995 Dec; 55(23 Suppl):5868s-5873s. PubMed ID: 7493362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
    Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
    Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a transgenic mouse model for anti-human CEA radioimmunotherapeutics.
    Wilkinson RW; Ross EL; Ellison D; Zimmermann W; Snary D; Mather SJ
    J Nucl Med; 2002 Oct; 43(10):1368-76. PubMed ID: 12368376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma].
    DU YF; Luo RC; Li GP; Li AM; Ding XM; Yan X; Huang K
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):460-2. PubMed ID: 18359714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.
    Li L; Xu HY; Mi L; Bian HJ; Qin J; Xiong H; Feng Q; Wen N; Tian R; Xu LQ; Shen XM; Tang H; Chen ZN
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1238-44. PubMed ID: 16979831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas.
    El Emir E; Qureshi U; Dearling JL; Boxer GM; Clatworthy I; Folarin AA; Robson MP; Nagl S; Konerding MA; Pedley RB
    Cancer Res; 2007 Dec; 67(24):11896-905. PubMed ID: 18089820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
    Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
    Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.